Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 150 No. 5153 (2020)

Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs

DOI
https://doi.org/10.4414/smw.2020.20446
Cite this as:
Swiss Med Wkly. 2020;150:w20446
Published
31.12.2020

Summary

AIMS OF THE STUDY

Hydroxychloroquine and lopinavir/ritonavir have been used as experimental therapies to treat COVID-19 during the first wave of the pandemic. Randomised controlled trials have recently shown that there are no meaningful benefits of these two therapies in hospitalised patients. Uncertainty remains regarding the potential harmful impact of these therapies as very early treatments and their burden to the health care system. The present study investigated the length of hospital stay (LOS), mortality, and costs of hydroxychloroquine, lopinavir/ritonavir or their combination in comparison with standard of care among patients hospitalised for coronavirus disease 2019 (COVID-19).

METHODS

This retrospective observational cohort study took place in the Geneva University Hospitals, Geneva, Switzerland (n = 840) between 26 February and 31 May 2020. Demographics, treatment regimens, comorbidities, the modified National Early Warning Score (mNEWS) on admission, and contraindications to COVID-19 treatment options were assessed. Outcomes included LOS, in-hospital mortality, and drug and LOS costs.

RESULTS

After successful propensity score matching, patients treated with (1) hydroxychloroquine, (2) lopinavir/ritonavir or (3) their combination had on average 3.75 additional hospitalisation days (95% confidence interval [CI] 1.37–6.12, p = 0.002), 1.23 additional hospitalisation days (95% CI −1.24 – 3.51, p = 0.319), and 4.19 additional hospitalisation days (95% CI 1.52–5.31, p <0.001), respectively, compared with patients treated with the standard of care. Neither experimental therapy was significantly associated with mortality. These additional hospital days amounted to 1010.77 additional days for hydroxychloroquine and hydroxychloroquine combined with lopinavir/ritonavir, resulting in an additional cost of US$ 2,492,214 (95%CI US$ 916,839–3,450,619).

CONCLUSIONS

Prescribing experimental therapies for COVID-19 was not associated with a reduced LOS and might have increased the pressure put on healthcare systems.

References

  1. Salathé M, Althaus CL, Neher R, Stringhini S, Hodcroft E, Fellay J, et al. COVID-19 epidemic in Switzerland: on the importance of testing, contact tracing and isolation. Swiss Med Wkly. 2020;150:w20225. doi:.https://doi.org/10.4414/smw.2020.20225
  2. Siemieniuk RAC, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020;370:m2980. doi:.https://doi.org/10.1136/bmj.m2980
  3. Horby PW, Mafham M, Bell JL, Linsell L, Staplin N, Emberson J, et al.; RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10259):1345–52 doi:.https://doi.org/10.1016/S0140-6736(20)32013-4
  4. Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al., RECOVERY Collaborative Group. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020;383(21):2030–40. doi:.https://doi.org/10.1056/NEJMoa2022926
  5. https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19 [accessed 2020 July 14].
  6. Griffin S. Covid-19: Lopinavir-ritonavir does not benefit hospitalised patients, UK trial finds. BMJ. 2020;370:m2650. doi:.https://doi.org/10.1136/bmj.m2650
  7. https://www.recoverytrial.net/news/no-clinical-benefit-from-use-of-lopinavir-ritonavir-in-hospitalised-covid-19-patients-studied-in-recovery [accessed 2020 July 14].
  8. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396(10247):313–9. doi:.https://doi.org/10.1016/S0140-6736(20)31304-0
  9. Prokop M, van Everdingen W, van Rees Vellinga T, Quarles van Ufford H, Stöger L, Beenen L, et al.; COVID-19 Standardized Reporting Working Group of the Dutch Radiological Society. CO-RADS: A Categorical CT Assessment Scheme for Patients Suspected of Having COVID-19-Definition and Evaluation. Radiology. 2020;296(2):E97–104. doi:.https://doi.org/10.1148/radiol.2020201473
  10. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382(25):2411–8. doi:.https://doi.org/10.1056/NEJMoa2012410
  11. Kalil AC. Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA. 2020;323(19):1897–8. doi:.https://doi.org/10.1001/jama.2020.4742
  12. Windisch O, Zamberg I, Zanella M-C, Gayet-Ageron A, Blondon K, Schiffer E, et al. Using mHealth to increase the reach of local guidance to health professionals as part of an institutional response plan to the COVID-19 outbreak: Usage analysis study. JMIR Mhealth Uhealth. 2020;8(8):e20025. doi:.https://doi.org/10.2196/20025
  13. Swiss DRG. Règles et définitions pour la facturation des cas selon SwissDRG. Bern, Switzerland: SwissDRG; 2018.
  14. Liao X, Wang B, Kang Y. Novel coronavirus infection during the 2019-2020 epidemic: preparing intensive care units-the experience in Sichuan Province, China. Intensive Care Med. 2020;46(2):357–60. doi:.https://doi.org/10.1007/s00134-020-05954-2
  15. Joseph BA, Dibas M, Evanson KW, Paranjape G, Vegivinti CTR, Selvan PT, et al. Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review. Expert Rev Anti Infect Ther. 2020;14787210.2021.1848545. doi:.https://doi.org/10.1080/14787210.2021.1848545
  16. Cortegiani A, Ippolito M, Ingoglia G, Iozzo P, Giarratano A, Einav S. Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. J Crit Care. 2020;59:176–90. doi:.https://doi.org/10.1016/j.jcrc.2020.06.019
  17. Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. CMAJ. 2020;192(17):E450–3. doi:.https://doi.org/10.1503/cmaj.200528
  18. Guastalegname M, Vallone A. Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment? Clin Infect Dis. 2020;71(15):888–9. doi:.https://doi.org/10.1093/cid/ciaa321
  19. Tanne JH. Covid-19: Trump is criticised for again promoting unorthodox medical information. BMJ. 2020;370:m3046. doi:.https://doi.org/10.1136/bmj.m3046
  20. Yazdany J, Kim AHJ. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know. Ann Intern Med. 2020;172(11):754–5. doi:.https://doi.org/10.7326/M20-1334
  21. Randomised evaluation of Covid-19 therapy (recovery) https://www.recoverytrial.net/files/protocol-archive/recovery-protocol-v6-0-2020-05-14.pdf/@@download [accessed 2020 July 14].
  22. Kim AHJ, Sparks JA, Liew JW, Putman MS, Berenbaum F, Duarte-García A, et al. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. Ann Intern Med. 2020;172(12):819–21. doi:.https://doi.org/10.7326/M20-1223
  23. Bonow RO, Hernandez AF, Turakhia M. Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation. JAMA Cardiol. 2020;5(9):986–7. doi:.https://doi.org/10.1001/jamacardio.2020.1782
  24. Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(9):1036–41. doi:.https://doi.org/10.1001/jamacardio.2020.1834
  25. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849. doi:.https://doi.org/10.1136/bmj.m1849
  26. Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al.; CloroCovid-19 Team. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open. 2020;3(4):e208857. doi:.https://doi.org/10.1001/jamanetworkopen.2020.8857
  27. Straw S, Witte KK. Observational data during the COVID-19 pandemic: opportunity with uncertainty. Heart. 2020;106(19):1461–2. doi:.https://doi.org/10.1136/heartjnl-2020-317486
  28. Lemos DRQ, D’Angelo SM, Farias LABG, Almeida MM, Gomes RG, Pinto GP, et al. Health system collapse 45 days after the detection of COVID-19 in Ceará, Northeast Brazil: a preliminary analysis. Rev Soc Bras Med Trop. 2020;53:e20200354. doi:.https://doi.org/10.1590/0037-8682-0354-2020
  29. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996;312(7040):1215–8. doi:.https://doi.org/10.1136/bmj.312.7040.1215
  30. Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet. 2005;365(9453):82–93. doi:.https://doi.org/10.1016/S0140-6736(04)17670-8

Most read articles by the same author(s)

1 2 3 > >>